Engineering the Antibody Fc Region for Optimal Effector Function

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 349-370

  Lazar, Greg A ^a   Desjarlais, John R ^a  

^a Xencor Inc   (United States)

Author keywords

Effector function silent Fc regions; Engineering antibody Fc region for optimal effector function; Engineering Fc for improved affinity to FcgRs

Indexed keywords

EID: 84864582259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch15     Document Type: Chapter

References (147)

1. Abdullah, N., J. Greenman, A. Pimenidou, K.P. Topping, and J.R. Monson. 1999. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunol. Immunother. 48(9):517-524.
2. Albertsson, P.A., P.H. Basse, M. Hokland, et al. 2003. NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity. Trends Immunol. 24(11):603-609.
3. Angal, S., D.J. King, M.W. Bodmer, et al. 1993. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30(1):105-108.
4. Armour, K.L., M.R. Clark, A.G. Hadley, and L.M. Williamson. 1999. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29(8):2613-2624.
5. Arnould, L., M. Gelly, F. Penault-Llorca, et al. 2006. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2):259-267.
6. Baker, M. 2006. Anti-infective antibodies: Finding the path forward. Nature Biotechnol. 24(12):1491-1493.
7. Bannerji, R., S. Kitada, I.W. Flinn, et al. 2003. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: rRelationship to in vivo rituximab resistance. J. Clin. Oncol. 21(8):1466-1471.
8. Beenhouwer, D.O., E.M. Yoo, C.W. Lai, M.A. Rocha, and S.L. Morrison. 2007. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect. Immun. 75(3):1424-1435.
9. Bolt, S., E. Routledge, I. Lloyd, et al. 1993. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23(2):403-411.
10. Boruchov, A.M., G. Heller, M.C. Veri, E. Bonvini, J.V. Ravetch, and J.W. Young. 2005. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115(10):2914-2923.
11. Bowles, J.A., and G.J. Weiner. 2005. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 304(1-2):88-99.
12. Bredius, R.G., C.A. Fijen, M. De Haas, et al. 1994. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1-and IgG3-opsonized bacteria and erythrocytes. Immunology 83(4):624-630.
13. Cartron, G., L. Dacheux, G. Salles, et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3):754-758.
14. Chatenoud, L. 2004. Anti-CD3 antibodies: Towards clinical antigen-specific immunomodulation. Curr. Opin. Pharmacol. 4(4):403-407.
15. Cheung, N.K., R. Sowers, A.J. Vickers, I.Y. Cheung, B.H. Kushner, and R. Gorlick. 2006. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulo-cyte macrophage colony-stimulating factor. J. Clin. Oncol. 24(18):2885-2890.
16. Clark, M.R. 1997. IgG effector mechanisms. Chem. Immunol. 65:88-110.
17. Clynes, R. 2006. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. NorthAm. 20(3):585-612.
18. Clynes, R., Y. Takechi, Y. Moroi, A. Houghton, and J.V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95(2):652-656.
19. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6(4):443-446.
20. Cole, M.S., C. Anasetti, and J.Y. Tso. 1997. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J. Immunol. 159(7):3613-3621.
21. Cox, K.M., J.D. Sterling, J.T. Regan, et al. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnol. 24(12):1591-1597.
22. Cragg, M.S., and M.J. Glennie. 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103(7):2738-2743.
23. Cragg, M.S., S.M. Morgan, H.T. Chan, et al. 2003. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101(3):1045-1052.
24. Dall'Acqua, W.F., K.E. Cook, M.M. Damschroder, R.M. Woods, and H. Wu. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177(2):1129-1138.
25. Davies, J., L. Jiang, L.Z. Pan, M.J. LaBarre, D. Anderson, and M. Reff. 2001. Expression of GnTIII in a recombi-nant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74(4):288-294.
26. Desjarlais, J.R., G.A. Lazar, E.A. Zhukovsky, and S.Y. Chu. 2007. Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective. Drug Discov. Today 12(21-22):898-910.
27. Dhodapkar, K.M., J.L. Kaufman, M. Ehlers, et al. 2005. Selective blockade of inhibitory Fcgammareceptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA. 102(8):2910-2915.
28. Dhodapkar, K.M., J. Krasovsky, B. Williamson, and M.V. Dhodapkar. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195(1):125-133.
29. Di Carlo, E., G. Forni, P. Lollini, M.P. Colombo, A. Modesti, and P. Musiani. 2001. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97(2):339-345.
30. Di Gaetano, N., E. Cittera, R. Nota, et al. 2003. Complement activation determines the therapeutic activity of ritux-imab in vivo. J. Immunol. 171(3):1581-1587.
31. Drescher, B., T. Witte, and R.E. Schmidt. 2003. Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity. Immunology 110(3):335-340.
32. Edberg, J.C., and R.P. Kimberly. 1997. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): Differential ligand binding. J. Immunol. 159(8):3849-3857.
33. Edberg, J.C., J.J. Moon, D.J. Chang, and R.P. Kimberly. 1998. Differential regulation of human neutrophil FcgammaRIIa (CD32) and FcgammaRIIIb (CD16)-induced Ca2+ transients. J. Biol. Chem. 273(14): 8071-8079.
34. Edelman, G.M., B.A. Cunningham, W.E. Gall, P.D. Gottlieb, U. Rutishauser, and M.J. Waxdal. 1969. The covalent structure of an entire gammaG immunoglobulin molecule. Proc. Natl. Acad. Sci. USA 63(1):78-85.
35. Ernst, L.K., D. Metes, R.B. Herberman, and P.A. Morel. 2002. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J. Mol. Med. 80(4):248-257.
36. Farag, S.S., I.W. Flinn, R. Modali, T.A. Lehman, D. Young, and J.C. Byrd. 2004. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103(4):1472-1474.
37. Fernandes, M.J., E. Rollet-Labelle, G. Pare, et al. 2006. CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem. J. 393(Pt 1):351-359.
38. Ferrara, C., F. Stuart, P. Sondermann, P. Brunker, and P. Umana. 2006. The carbohydrate at FcgammaRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281(8):5032-5036.
39. Forero, A., J. Shah, R. Carlisle, et al. 2006. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother. Radiopharm. 21(6):561-568.
40. Friend, P.J., G. Hale, L. Chatenoud, et al. 1999. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68(11):1632-1637.
41. Gelderman, K.A., S. Tomlinson, G.D. Ross, and A. Gorter. 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25(3):158-164.
42. Gillies, S.D., Y. Lan, K.M. Lo, M. Super, J. Wesolowski. 1999. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res. 59(9):2159-2166.
43. Godau, J., T. Heller, H. Hawlisch, et al. 2004. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173(5):3437-3445.
44. Golay, J., E. Cittera, N. Di Gaetano, et al. 2006. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91(2):176-183.
45. Guiducci, C., A.P. Vicari, S. Sangaletti, G. Trinchieri, and M.P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65(8):3437-3446.
46. Hamaguchi, Y., J. Uchida, D.W. Cain, et al. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174(7):4389-4399.
47. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmeijahn, and T.F. Tedder. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203(3):743-753.
48. Han, Y., T.R. Kozel, M.X. Zhang, R.S. MacGill, M.C. Carroll, and J.E. Cutler. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167(3):1550-1557.
49. Hatjiharissi, E., M. Hansen, D.D. Santos, et al. 2007. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin. Lymphoma Myeloma 7(4):286-290.
50. Hezareh, M., A.J. Hessell, R.C. Jensen, J.G. van de Winkel, and P.W. Parren. 2001. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75(24):12161-12168.
51. Horton, H.H., M.J. Bernett, E.K. Pong, et al. 2008. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68(19):8049-8057.
52. Hutchins, J.T., F.C. Kull, Jr., J. Bynum, V.C. Knick, L.M. Thurmond, and P. Ray. 1995. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc. Natl. Acad. Sci. USA 92(26):11980-11984.
53. Idusogie, E.E., L.G. Presta, H. Gazzano-Santoro, et al. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164(8):4178-4184.
54. Idusogie, E.E., P.Y. Wong, L.G. Presta, et al. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166(4):2571-2575.
55. Imai, M., C. Landen, R. Ohta, N.K. Cheung, and S. Tomlinson. 2005. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 65(22):10562-10568.
56. Isaacs, J.D., M.G. Wing, J.D. Greenwood, B.L. Hazleman, G. Hale, and H. Waldmann. 1996. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106(3):427-433.
57. Kabat, E.A., T.T. Wu, H.M. Perry, K.S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest. Bethesda, MD: U.S. Department of Health and Human Services.
58. Kanda, Y., T. Yamada, K. Mori, et al. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1):104-118.
59. Karassa, F.B., T.A. Trikalinos, and J.P. Ioannidis. 2004. The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomed. Pharmacother. 58(5):286-291.
60. Kashii, Y., R. Giorda, R.B. Herberman, T.L. Whiteside, and N.L. Vujanovic. 1999. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 163(10): 5358-5366.
61. Kelly-Quintos, C., L.A. Cavacini, M.R. Posner, D. Goldmann, and G.B. Pier. 2006. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect. Immun. 74(5):2742-2750.
62. Kennedy, A.D., P.V. Beum, M.D. Solga, et al. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172(5):3280-3288.
63. Kim, D.H., H.D. Jung, J.G. Kim, et al. 2006. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108(8):2720-2725.
64. Koene, H.R., M. Kleijer, J. Algra, D. Roos, A.E. von dem Borne, and M. de Haas. 1997. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90(3):1109-1114.
65. Kono, H., C. Kyogoku, T. Suzuki, et al. 2005. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14(19):2881-2892.
66. Konrad, S., U. Baumann, R.E. Schmidt, and J.E. Gessner. 2006. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: A direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br. J. Haematol. 134(3):345-347.
67. Lazar, G.A., W. Dang, S. Karki, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103(11):4005-4010.
68. Lehrnbecher, T., C.B. Foster, S. Zhu, et al. 1999. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 94(12):4220-4232.
69. Li, H., N. Sethuraman, T.A. Stadheim, et al. 2006. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnol. 24(2):210-215.
70. Li, L., I. Spendlove, J. Morgan, and L.G. Durrant. 2001. CD55 is over-expressed in the tumour environment. Br. J. Cancer 84(1):80-86.
71. Li, X., J. Wu, R.H. Carter, et al. 2003. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 48(11):3242-3252.
72. Lifely, M.R., C. Hale, S. Boyce, M.J. Keen, and J. Phillips. 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5(8):813-822.
73. Macor, P., D. Mezzanzanica, C. Cossetti, et al. 2006. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res. 66(7):3876-3883.
74. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23(11):549-555.
75. Martin, W.L., A.P. West, Jr., L. Gan, and P.J. Bjorkman. 2001. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: Mechanism of pH-dependent binding. Mol. Cell 7(4):867-877.
76. Masuda, K., T. Kubota, E. Kaneko, et al. 2007. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 44(12):3122-3131.
77. Matsumiya, S., Y. Yamaguchi, J. Saito, et al. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368(3):767-779.
78. Meng, R., J.E. Smallshaw, L.M. Pop, et al. 2004. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin. CancerRes. 10(4):1274-1281.
79. Michaelsen, T.E., J.E. Thommesen, O. Ihle, et al. 2006. A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. Eur. J. Immunol. 36(1):129-138.
80. Michon, J.M., A. Gey, S. Moutel, et al. 1998. In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br. J. Haematol. 100(3):550-556.
81. Mitrovic, Z., I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar. 2007. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92(7):998-999.
82. Musolino, A., N. Naldi, B. Bortesi, et al. 2007. Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer. Presented at the AACR Annual Meeting Los Angeles.
83. Nagarajan, S., S. Chesla, L. Cobern, P. Anderson, C. Zhu, and P. Selvaraj. 1995. Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells. J. Biol. Chem. 270(43):25762-25770.
84. Nagarajan, S., K. Venkiteswaran, M. Anderson, U. Sayed, C. Zhu, and P. Selvaraj. 2000. Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 95(3):1069-1077.
85. Natsume, A., M. In, H. Takamura, et al. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68(10):3863-3872.
86. Nechansky, A., M. Schuster, W. Jost, et al. 2007. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol. Immunol. 44(7):1815-1817.
87. Newman, R., K. Hariharan, M. Reff, et al. 2001. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin. Immunol. 98(2):164-174.
88. Nimmerjahn, F., and J.V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512.
89. Niwa, R., E. Shoji-Hosaka, M. Sakurada, et al. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64(6):2127-2133.
90. Norman, D.J., F. Vincenti, A.M. deMattos, et al. 2000. PhaseItrial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70(12):1707-1712.
91. Okazaki, A., E. Shoji-Hosaka, K. Nakamura, et al. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 5 336(5):1239-1249.
92. Parren, P.W., P.A. Warmerdam, L.C. Boeije, et al. 1992. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90(4):1537-1546.
93. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer. 4(1):71-78.
94. Preston, M.J., A.A. Gerceker, M.E. Reff, and G.B. Pier. 1998. Production and characterization of a set of mousehuman chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infect. Immun. 66(9): 4137-4142.
95. Pricop, L., P. Redecha, J.L. Teillaud, et al. 2001. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166(1):531-537.
96. Raasveld, M.H., F.J. Bemelman, P.T. Schellekens, et al. 1993. Complement activation during OKT3 treatment: A possible explanation for respiratory side effects. Kidney Int. 43(5):1140-1149.
97. Racila, E., D.M. Racila, J.M. Ritchie, C. Taylor, C. Dahle, and G.J. Weiner. 2006. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 58(1):1-8.
98. Radaev, S., S. Motyka, W.H. Fridman, C. Sautes-Fridman, and P.D. Sun. 2001. The structure of a human type III Fcg receptor in complex with Fc. J. Biol. Chem. 276(19):16469-16477.
99. Reddy, M.P., C.A. Kinney, M.A. Chaikin, et al. 2000. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164(4):1925-1933.
100. Redpath, S., T. Michaelsen, I. Sandlie, and M.R. Clark. 1998. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology 93(4):595-600.
101. Richards, J.O., S. Karki, G.A. Lazar, H. Chen, W. Dang, and J.R. Desjarlais. 2008. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7(8):2517-2527.
102. Salfeld, J.G. 2007. Isotype selection in antibody engineering. Nature Biotechnol. 25(12):1369-1372.
103. Salmon, J.E., J.C. Edberg, N.L. Brogle, and R.P. Kimberly. 1992. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 89(4):1274-1281.
104. Salmon, J.E., S.S. Millard, N.L. Brogle, and R.P. Kimberly. 1995. Fc gamma receptor IIIb enhances Fc gamma receptor IIa function in an oxidant-dependent and allele-sensitive manner. J. Clin. Invest. 95(6):2877-2885.
105. Sanders, L.A., R.G. Feldman, M.M. Voorhorst-Ogink, et al. 1995. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun. 63(1):73-81.
106. Saphire, E.O., R.L. Stanfield, M.D. Crispin, et al. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319(1):9-18.
107. Scallon, B.J., S.H. Tam, S.G. McCarthy, A.N. Cai, and T.S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44(7):1524-1534.
108. Schakel, K., E. Mayer, C. Federle, M. Schmitz, G. Riethmuller, and E.P. Rieber. 1998. A novel dendritic cell population in human blood: One-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28(12):4084-4093.
109. Selenko, N., O. Majdic, U. Jager, C. Sillaber, J. Stockl, and W. Knapp. 2002. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol. 22(3):124-130.
110. Sensel, M.G., L.M. Kane, and S.L. Morrison. 1997. Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement. Mol. Immunol. 34(14):1019-1029.
111. Shields, R.L., J. Lai, R. Keck, et al. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30):26733-26740.
112. Shields, R.L., A.K. Namenuk, K. Hong, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276(9):6591-6604.
113. Shinkawa, T., K. Nakamura, N. Yamane, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(5):3466-3473.
114. Shopes, B. 1992. A genetically engineered human IgG mutant with enhanced cytolytic activity. J. Immunol. 148(9):2918-2922.
115. Siberil, S., C. de Romeuf, N. Bihoreau, et al. 2006. Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin. Immunol. 118(2-3):170-179.
116. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcgRIII complex. Nature 406(6793):267-273.
117. Sondermann, P., J. Kaiser, and U. Jacob. 2001. Molecular basis for immune complex recognition: A comparison of Fc-receptor structures. J. Mol. Biol. 309(3):737-749.
118. Spiridon, C.I., M.A. Ghetie, J. Uhr, et al. 2002. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8(6):1720-1730.
119. Stavenhagen, J.B., S. Gorlatov, N. Tuaillon, et al. 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc gamma receptors. CancerRes. 67(18):8882-8890.
120. Stockinger, H. 1997. Interaction of GPI-anchored cell surface proteins and complement receptor type 3. Exp. Clin. Immunogenet. 14(1):5-10.
121. Strohl, W.R. 2006 (Oct. 17). Non-immunostimulatory antibody and compositions containing the same. USSN 11/581,931.
122. Tao, M.H., S.M. Canfield, and S.L. Morrison. 1991. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 173(4):1025-1028.
123. Tao, M.H., R.I. Smith, and S.L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178(2):661-667.
124. Tawara, T., K. Hasegawa, Y. Sugiura, et al. 2008. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J. Immunol. 180(4):2294-2298.
125. Thommesen, J.E., T.E. Michaelsen, G.A. Loset, I. Sandlie, and O.H. Brekke. 2000. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol. Immunol. 37(16): 995-1004.
126. Treon, S.P., M. Hansen, A.R. Branagan, et al. 2005. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol. 23(3):474-481.
127. Treon, S.P., C. Mitsiades, N. Mitsiades, et al. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24(3):263-271.
128. Uchida, J., Y. Hamaguchi, J.A. Oliver, et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199(12):1659-1669.
129. Umana, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J.E. Bailey. 1999. Engineered glycoforms of an antineur-oblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol. 17(2):176-180.
130. Vallhonrat, H., W.W. Williams, A.B. Cosimi, et al. 1999. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 67(2):253-258.
131. van der Neut Kolfschoten, M., J. Schuurman, M. Losen, et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317(5844):1554-1557.
132. Van Egmond, M. 2008. Neutrophils in antibody-based immunotherapy of cancer. Expert Opin. Biol. Ther. 8(1):83-94.
133. Van Ginderachter, J.A., K. Movahedi, G. Hassanzadeh Ghassabeh, et al. 2006. Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology 211(6-8):487-501.
134. von Sorge, N.M., W.L. von der Pol, and J.G. von de Winkel. 2003. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61(3):189-202.
135. Wells, J., C.G. Haidaris, T.W. Wright, and F. Gigliotti. 2006. Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect. Immun. 74(1):390-393.
136. Weng, W.K., and R. Levy. 2001. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98(5):1352-1357.
137. Weng, W.K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21):3940-3947.
138. Weng, W.K., and R. Levy. 2005. Genetic polymorphism of the inhibitory IgG Fc receptor Fc gamma RIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients. ASH Annual Meeting, Atlanta. Vol. 106, 2430.
139. West, A.P., Jr., and P.J. Bjorkman. 2000. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39(32):9698-9708.
140. Wise, M.P., A. Gallimore, A. Godkin. 2006. T-cell costimulation. N. Engl. J. Med. 355(24):2594-2595; author reply 2595.
141. Woodle, E.S., D. Xu, R.A. Zivin, et al. 1999. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68(5):608-616.
142. Xia, M.Q., G. Hale, and H. Waldmann. 1993. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 30(12):1089-1096.
143. Xu, D., M.L. Alegre, S.S. Varga, et al. 2000. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200(1):16-26.
144. Yamane-Ohnuki, N., S. Kinoshita, M. Inoue-Urakubo, et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87(5):614-622.
145. Yoo, E.M., L.A. Wims, L.A. Chan, and S.L. Morrison. 2003. Human IgG2 can form covalent dimers. J. Immunol. 170(6):3134-3138.
146. Zalevsky, J., I.W. Leung, S. Karki, et al. 2009. The impact of Fc engineering on an anti-CD19 antibody: increased Fc gamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113:3735-3743.
147. Zhang, W., M. Gordon, A.M. Schultheis, et al. 2007. FCGR2Aand FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25(24):3712-3718.